A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs SGM 1019 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Second Genome
- 09 Jul 2019 Status changed from recruiting to discontinued.
- 26 Mar 2019 According to a Second Genome media release, the company expects to complete this phase 2a clinical trial in NASH in early 2020.
- 05 Feb 2019 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.